First Procedure Completed in London
ATU iHub Client Company, Endowave has reached a major point in the Aurora clinical study with the first ever procedure using the FlexAblate transbronchial microwave ablation catheter in a lung cancer patient. The procedure took place in St. Bart’s Hospital London during lung cancer awareness month, adding further weight to the achievement. Kelvin Lau and his team carried out the treatment using robotic assisted bronchoscopy and real time Cone Beam CT imaging to guide the FlexAblate catheter to a tumour located in the periphery of the lung. This was the first time the system had been used in a clinical setting on a lung cancer patient after years of development by the Endowave team. The successful delivery of the catheter confirmed that the system can reach peripheral lesions through a minimally invasive route. The team at St. Bart’s will continue to work with Endowave as the study progresses.
First Five Clinical Cases Completed Across Two Centres
The Aurora study advanced further with the completion of the first five clinical cases across two leading European centres. Kelvin Lau’s team in St. Bart’s Hospital London and Agathe Seguin‑Givelet’s team in Ambroise Paré Hospital Paris performed the procedures. These cases included the first use of the FlexAblate system in combination with robotic assisted bronchoscopy and integrated mobile Cone Beam CT imaging in Paris. This combination allowed precise navigation and real time imaging during the procedure. The completion of these first in human cases marks a significant step in assessing the FlexAblate system as a new minimally invasive treatment option for lung cancer patients. The work reflects strong collaboration between clinical teams in London and Paris and years of technical development by Endowave. The company will share further updates at the J.P. Morgan Healthcare Conference 2026 from 12 to 14 January.
